Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

c-Myc (MYC); phosphoribosyl pyrophosphate synthetase 2 (PRPS2)

Mouse studies suggest inhibiting PRPS2 could help treat cancers driven by MYC. In a Myc-dependent mouse model of Burkitt lymphoma, high rates of protein and nucleotide synthesis were linked through translational upregulation of Prps2, a rate-limiting enzyme for the synthesis of purines. In the model, knockout of Prps2 delayed tumor initiation and prolonged survival without affecting other cell types. Next steps include antagonizing PRPS2 in additional MYC-driven tumor types and developing a specific inhibitor of PRPS2.

SciBX 7(25); doi:10.1038/scibx.2014.730
Published online June 26, 2014

Patent application filed by the University of California, San Francisco; licensed to Effector Therapeutics Inc.

Cunningham, J.T. et al. Cell; published online May 22, 2014;
doi:10.1016/j.cell.2014.03.052
Contact: Davide Ruggero, University of California, San Francisco, Calif.
e-mail:

davide.ruggero@ucsf.edu